Clinical standards for drug-susceptible TB in children and adolescents
BACKGROUND: These clinical standards aim to provide guidance for diagnosis, treatment, and management of drug-susceptible TB in children and adolescents.METHODS: Fifty-two global experts in paediatric TB participated in a Delphi consensus process. After eight rounds of revisions, 51/52 (98%) participants endorsed the final document.RESULTS: Eight standards were identified: Standard 1, Age and developmental stage are critical considerations in the assessment and management of TB; Standard 2, Children and adolescents with symptoms and signs of TB disease should undergo prompt evaluation, and diagnosis and treatment initiation should not depend on microbiological confirmation; Standard 3, Treatment initiation is particularly urgent in children and adolescents with presumptive TB meningitis and disseminated (miliary) TB; Standard 4, Children and adolescents should be treated with an appropriate weight-based regimen; Standard 5, Treating TB infection (TBI) is important to prevent disease; Standard 6, Children and adolescents should receive home-based/community-based treatment support whenever possible; Standard 7, Children, adolescents, and their families should be provided age-appropriate support to optimise engagement in care and clinical outcomes; and Standard 8, Case reporting and contact tracing should be conducted for each child and adolescent.CONCLUSION: These consensus-based clinical standards, which should be adapted to local contexts, will improve the care of children and adolescents affected by TB.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease - 27(2023), 8 vom: 01. Aug., Seite 584-598 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chiang, S S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Journal Article |
|---|
| Anmerkungen: |
Date Completed 01.08.2023 Date Revised 07.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.5588/ijtld.23.0085 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359919189 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359919189 | ||
| 003 | DE-627 | ||
| 005 | 20231226081912.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5588/ijtld.23.0085 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359919189 | ||
| 035 | |a (NLM)37491754 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chiang, S S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical standards for drug-susceptible TB in children and adolescents |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.08.2023 | ||
| 500 | |a Date Revised 07.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: These clinical standards aim to provide guidance for diagnosis, treatment, and management of drug-susceptible TB in children and adolescents.METHODS: Fifty-two global experts in paediatric TB participated in a Delphi consensus process. After eight rounds of revisions, 51/52 (98%) participants endorsed the final document.RESULTS: Eight standards were identified: Standard 1, Age and developmental stage are critical considerations in the assessment and management of TB; Standard 2, Children and adolescents with symptoms and signs of TB disease should undergo prompt evaluation, and diagnosis and treatment initiation should not depend on microbiological confirmation; Standard 3, Treatment initiation is particularly urgent in children and adolescents with presumptive TB meningitis and disseminated (miliary) TB; Standard 4, Children and adolescents should be treated with an appropriate weight-based regimen; Standard 5, Treating TB infection (TBI) is important to prevent disease; Standard 6, Children and adolescents should receive home-based/community-based treatment support whenever possible; Standard 7, Children, adolescents, and their families should be provided age-appropriate support to optimise engagement in care and clinical outcomes; and Standard 8, Case reporting and contact tracing should be conducted for each child and adolescent.CONCLUSION: These consensus-based clinical standards, which should be adapted to local contexts, will improve the care of children and adolescents affected by TB | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a Graham, S M |e verfasserin |4 aut | |
| 700 | 1 | |a Schaaf, H S |e verfasserin |4 aut | |
| 700 | 1 | |a Marais, B J |e verfasserin |4 aut | |
| 700 | 1 | |a Sant'Anna, C C |e verfasserin |4 aut | |
| 700 | 1 | |a Sharma, S |e verfasserin |4 aut | |
| 700 | 1 | |a Starke, J R |e verfasserin |4 aut | |
| 700 | 1 | |a Triasih, R |e verfasserin |4 aut | |
| 700 | 1 | |a Achar, J |e verfasserin |4 aut | |
| 700 | 1 | |a Amanullah, F |e verfasserin |4 aut | |
| 700 | 1 | |a Armitage, L Y |e verfasserin |4 aut | |
| 700 | 1 | |a Aurilio, R B |e verfasserin |4 aut | |
| 700 | 1 | |a Buck, W C |e verfasserin |4 aut | |
| 700 | 1 | |a Centis, R |e verfasserin |4 aut | |
| 700 | 1 | |a Chabala, C |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz, A T |e verfasserin |4 aut | |
| 700 | 1 | |a Demers, A-M |e verfasserin |4 aut | |
| 700 | 1 | |a du Preez, K |e verfasserin |4 aut | |
| 700 | 1 | |a Enimil, A |e verfasserin |4 aut | |
| 700 | 1 | |a Furin, J |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Prats, A J |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez, N E |e verfasserin |4 aut | |
| 700 | 1 | |a Hoddinott, G |e verfasserin |4 aut | |
| 700 | 1 | |a Isaakidis, P |e verfasserin |4 aut | |
| 700 | 1 | |a Jaganath, D |e verfasserin |4 aut | |
| 700 | 1 | |a Kabra, S K |e verfasserin |4 aut | |
| 700 | 1 | |a Kampmann, B |e verfasserin |4 aut | |
| 700 | 1 | |a Kay, A |e verfasserin |4 aut | |
| 700 | 1 | |a Kitai, I |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez-Varela, E |e verfasserin |4 aut | |
| 700 | 1 | |a Maleche-Obimbo, E |e verfasserin |4 aut | |
| 700 | 1 | |a Malaspina, F Mestanza |e verfasserin |4 aut | |
| 700 | 1 | |a Velásquez, J Niederbacher |e verfasserin |4 aut | |
| 700 | 1 | |a Nuttall, J J C |e verfasserin |4 aut | |
| 700 | 1 | |a Oliwa, J N |e verfasserin |4 aut | |
| 700 | 1 | |a Andrade, I Orozco |e verfasserin |4 aut | |
| 700 | 1 | |a Perez-Velez, C M |e verfasserin |4 aut | |
| 700 | 1 | |a Rabie, H |e verfasserin |4 aut | |
| 700 | 1 | |a Seddon, J A |e verfasserin |4 aut | |
| 700 | 1 | |a Sekadde, M P |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, A |e verfasserin |4 aut | |
| 700 | 1 | |a Skrahina, A |e verfasserin |4 aut | |
| 700 | 1 | |a Soriano-Arandes, A |e verfasserin |4 aut | |
| 700 | 1 | |a Steenhoff, A P |e verfasserin |4 aut | |
| 700 | 1 | |a Tebruegge, M |e verfasserin |4 aut | |
| 700 | 1 | |a Tovar, M A |e verfasserin |4 aut | |
| 700 | 1 | |a Tsogt, B |e verfasserin |4 aut | |
| 700 | 1 | |a van der Zalm, M M |e verfasserin |4 aut | |
| 700 | 1 | |a Welch, H |e verfasserin |4 aut | |
| 700 | 1 | |a Migliori, G B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease |d 1998 |g 27(2023), 8 vom: 01. Aug., Seite 584-598 |w (DE-627)NLM093757409 |x 1815-7920 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:8 |g day:01 |g month:08 |g pages:584-598 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5588/ijtld.23.0085 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 8 |b 01 |c 08 |h 584-598 | ||